VRCA Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 42.60%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $411,790.55

Verrica Pharmaceuticals Insider Trading History Chart

Verrica Pharmaceuticals Share Price & Price History

^$0.43

▼ -0.0045 (-1.03%)

As of 03/28/2025 05:00 PM ET

Days: 30 | 90 | 365

Verrica Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/17/2025	Christopher G. Hayes	Insider	Sell	4,315	$0.65	$2,804.75	176,458
7/22/2024	Joe Bonaccorso	Insider	Sell	25,461	$7.06	$179,754.66	106,931
7/22/2024	Ted White	CEO	Sell	32,469	$7.06	$229,231.14	250,121
12/28/2023	Perceptive Advisors Llc	Major Shareholder	Buy	126,116	$7.08	$892,901.28	6,983,408
12/26/2023	Perceptive Advisors Llc	Major Shareholder	Buy	54,652	$6.49	$354,691.48	6,777,566
12/21/2023	Perceptive Advisors Llc	Major Shareholder	Buy	200,000	$6.17	$1,234,000.00	6,472,914
12/18/2023	Perceptive Advisors Llc	Major Shareholder	Buy	456,923	$5.41	$2,471,953.43	5,995,906
12/15/2023	Perceptive Advisors Llc	Major Shareholder	Buy	500,000	$5.97	$2,985,000.00	5,538,983
11/14/2023	Joe Bonaccorso	Insider	Sell	21,580	$2.93	$63,229.40	103,658
7/24/2023	Christopher G. Hayes	Insider	Sell	33,789	$4.83	$163,200.87	81,925
7/24/2023	Paul B. Manning	Director	Buy	200,000	$5.02	$1,004,000.00	7,851,128
7/24/2023	Ted White	CEO	Sell	50,677	$4.83	$244,769.91	128,789
7/11/2022	Christopher G. Hayes	Insider	Buy	7,500	$3.40	$25,500.00	15,714
7/5/2022	Christopher G. Hayes	Insider	Buy	5,714	$2.10	$11,999.40	8,214
7/5/2022	John A Stalfort III	Director	Buy	238,095	$2.10	$499,999.50	700,205
7/5/2022	Perceptive Advisors Llc	Major Shareholder	Buy	1,428,571	$2.10	$2,999,999.10	5,038,983
7/5/2022	Ted White	CEO	Buy	23,809	$2.10	$49,998.90	29,466

See Full Table

SEC Filings (Institutional Ownership Changes) for Verrica Pharmaceuticals (NASDAQ:VRCA)

42.45% of Verrica Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Verrica Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
2/17/2025	Bank of America Corp DE	143,818	$0.10M	0.0%	+347.5%	0.315%
2/14/2025	Caligan Partners LP	7,429,687	$5.20M	1.4%	N/A	16.293%
2/14/2025	Boothbay Fund Management LLC	2,587,046	$1.81M	0.0%	N/A	5.673%
2/14/2025	Heights Capital Management Inc.	351,142	$0.25M	0.1%	N/A	0.770%
2/13/2025	XTX Topco Ltd	48,084	$34K	0.0%	-79.2%	0.105%
2/13/2025	Renaissance Technologies LLC	233,300	$0.16M	0.0%	+57.7%	0.512%
2/13/2025	Invesco Ltd.	45,132	$32K	0.0%	N/A	0.099%
2/12/2025	Geode Capital Management LLC	477,269	$0.33M	0.0%	+4.8%	1.047%
1/30/2025	Rhumbline Advisers	266,093	$0.19M	0.0%	+975.2%	0.584%
1/29/2025	Sovran Advisors LLC	407,050	$0.27M	0.0%	N/A	0.893%
1/23/2025	SteelPeak Wealth LLC	76,000	$53K	0.0%	-25.5%	0.167%
11/25/2024	Sanctuary Advisors LLC	60,000	$87K	0.0%	N/A	0.132%
11/19/2024	Barclays PLC	31,341	$45K	0.0%	+404.6%	0.069%
11/15/2024	Barclays PLC	31,341	$45K	0.0%	+404.6%	0.069%
11/15/2024	XTX Topco Ltd	231,148	$0.34M	0.0%	N/A	0.507%
11/15/2024	Jane Street Group LLC	69,872	$0.10M	0.0%	+106.5%	0.153%
11/15/2024	State Street Corp	512,821	$0.74M	0.0%	+13.5%	1.125%
11/14/2024	Verition Fund Management LLC	61,640	$89K	0.0%	N/A	0.135%
11/13/2024	Propel Bio Management LLC	344,937	$0.50M	0.3%	-18.8%	0.756%
11/13/2024	FMR LLC	634,310	$0.92M	0.0%	-42.8%	1.391%
11/6/2024	Simplify Asset Management Inc.	200,000	$0.29M	0.0%	-28.6%	0.469%
10/25/2024	SteelPeak Wealth LLC	101,998	$0.15M	0.0%	-17.0%	0.240%
10/11/2024	Creative Planning	19,018	$28K	0.0%	-36.4%	0.045%
8/13/2024	Simplify Asset Management Inc.	280,000	$2.04M	0.1%	N/A	0.660%
8/9/2024	Renaissance Technologies LLC	45,525	$0.33M	0.0%	N/A	0.107%
8/6/2024	Quest Partners LLC	6,926	$50K	0.0%	N/A	0.016%
8/1/2024	Rhumbline Advisers	26,591	$0.19M	0.0%	+20.4%	0.063%
7/30/2024	Key Financial Inc	9,415	$69K	0.0%	N/A	0.022%
7/26/2024	Bank of New York Mellon Corp	58,680	$0.43M	0.0%	+8.1%	0.138%
7/18/2024	Miracle Mile Advisors LLC	84,000	$0.61M	0.0%	-28.9%	0.198%
7/17/2024	SteelPeak Wealth LLC	122,836	$0.90M	0.0%	-10.9%	0.290%
5/10/2024	Vanguard Group Inc.	1,268,710	$7.51M	0.0%	+0.6%	2.991%
5/1/2024	BNP Paribas Financial Markets	10,342	$61K	0.0%	-74.1%	0.024%
2/26/2024	Perceptive Advisors LLC	7,099,182	$51.97M	1.2%	+40.9%	16.879%
2/14/2024	Avoro Capital Advisors LLC	3,999,999	$29.28M	0.4%	+35.4%	9.510%
2/2/2024	Truist Financial Corp	10,545	$77K	0.0%	-33.8%	0.025%
1/31/2024	Kornitzer Capital Management Inc. KS	74,251	$0.54M	0.0%	-25.2%	0.177%
1/30/2024	BML Capital Management LLC	180,000	$1.32M	1.0%	+20.0%	0.428%
11/13/2023	FMR LLC	1,504,716	$5.85M	0.0%	+29.4%	3.578%
11/9/2023	Kovitz Investment Group Partners LLC	50,125	$0.20M	0.0%	+44.3%	0.119%
11/7/2023	New York State Common Retirement Fund	9,123	$35K	0.0%	-44.4%	0.022%
11/7/2023	Jump Financial LLC	18,200	$71K	0.0%	N/A	0.043%
10/31/2023	Kornitzer Capital Management Inc. KS	99,251	$0.39M	0.0%	-23.2%	0.236%
8/4/2023	American International Group Inc.	10,048	$58K	0.0%	N/A	0.024%
8/3/2023	SPC Financial Inc.	30,000	$0.17M	0.0%	N/A	0.072%
8/1/2023	Truist Financial Corp	15,928	$92K	0.0%	+41.0%	0.038%
7/24/2023	Vontobel Holding Ltd.	13,570	$78K	0.0%	N/A	0.032%
5/16/2023	Avoro Capital Advisors LLC	2,650,000	$17.23M	0.3%	N/A	6.316%
5/11/2023	Kovitz Investment Group Partners LLC	34,725	$0.23M	0.0%	+15.3%	0.083%
5/9/2023	Manchester Capital Management LLC	10,000	$65K	0.0%	N/A	0.024%
5/3/2023	Jump Financial LLC	29,909	$0.19M	0.0%	N/A	0.071%
4/20/2023	Miracle Mile Advisors LLC	118,221	$0.77M	0.0%	-5.4%	0.282%
4/19/2023	Legacy Trust	18,750	$0.12M	0.0%	N/A	0.045%
4/14/2023	BML Capital Management LLC	150,000	$0.98M	0.8%	-86.5%	0.358%
2/13/2023	BML Capital Management LLC	1,110,605	$3.05M	2.9%	N/A	2.703%
2/10/2023	Fosun International Ltd	129,013	$0.36M	0.0%	-54.3%	0.314%
2/8/2023	Conning Inc.	129,013	$0.36M	0.0%	N/A	0.314%
1/19/2023	Kovitz Investment Group Partners LLC	30,125	$83K	0.0%	N/A	0.073%
11/14/2022	Point72 Asset Management L.P.	485,802	$1.42M	0.0%	-35.6%	1.182%
11/14/2022	MML Investors Services LLC	89,950	$0.26M	0.0%	+104.9%	0.219%
11/7/2022	Virtu Financial LLC	10,834	$32K	0.0%	-56.1%	0.026%
11/3/2022	Creative Planning	14,781	$43K	0.0%	N/A	0.036%
8/16/2022	CVI Holdings LLC	450,000	$0.86M	0.1%	N/A	1.635%
8/3/2022	Kornitzer Capital Management Inc. KS	129,251	$0.25M	0.0%	-81.8%	0.470%
7/15/2022	Miracle Mile Advisors LLC	125,000	$0.24M	0.0%	N/A	0.454%
4/22/2022	Truist Financial Corp	11,298	$92K	0.0%	N/A	0.041%
2/14/2022	PDT Partners LLC	10,800	$99K	0.0%	N/A	0.039%
2/14/2022	Altium Capital Management LP	97,887	$0.90M	0.2%	-61.8%	0.356%
2/3/2022	Nisa Investment Advisors LLC	3,100	$25K	0.0%	-31.1%	0.011%
2/1/2022	Kornitzer Capital Management Inc. KS	708,976	$6.49M	0.1%	-2.6%	2.576%
1/28/2022	Allspring Global Investments Holdings LLC	5,703	$52K	0.0%	N/A	0.021%
11/17/2021	Altium Capital Management LP	256,244	$3.20M	0.7%	-51.2%	0.931%
11/16/2021	MML Investors Services LLC	44,875	$0.56M	0.0%	+30.2%	0.163%
11/15/2021	HighVista Strategies LLC	10,944	$0.14M	0.1%	N/A	0.040%
11/12/2021	Geode Capital Management LLC	238,069	$2.98M	0.0%	+11.8%	0.865%
11/9/2021	Barclays PLC	5,352	$67K	0.0%	+213.5%	0.019%
11/9/2021	BlackRock Inc.	645,218	$8.07M	0.0%	-8.2%	2.345%
8/25/2021	Marshall Wace LLP	31,425	$0.36M	0.0%	N/A	0.114%
8/17/2021	Millennium Management LLC	319,552	$3.61M	0.0%	+856.2%	1.161%
8/16/2021	PDT Partners LLC	16,200	$0.18M	0.0%	N/A	0.059%
8/16/2021	State Street Corp	214,347	$2.42M	0.0%	-1.8%	0.779%
8/16/2021	Marshall Wace LLP	31,425	$0.36M	0.0%	N/A	0.114%
8/16/2021	MML Investors Services LLC	34,475	$0.39M	0.0%	+63.6%	0.125%
8/13/2021	Northern Trust Corp	146,918	$1.66M	0.0%	-3.3%	0.534%
8/13/2021	Altium Capital Management LP	525,127	$5.93M	1.4%	-6.7%	1.909%
8/13/2021	Jump Financial LLC	16,474	$0.19M	0.0%	N/A	0.060%
8/13/2021	Geode Capital Management LLC	212,980	$2.41M	0.0%	+6.9%	0.777%
8/13/2021	Vanguard Group Inc.	687,811	$7.77M	0.0%	-3.2%	2.509%
8/12/2021	Dimensional Fund Advisors LP	21,461	$0.24M	0.0%	N/A	0.078%
8/12/2021	JPMorgan Chase & Co.	43,343	$0.49M	0.0%	+56.2%	0.158%
8/11/2021	Bank of New York Mellon Corp	42,203	$0.48M	0.0%	-4.2%	0.154%
8/11/2021	BlackRock Inc.	702,843	$7.94M	0.0%	+0.2%	2.564%
8/9/2021	Meeder Asset Management Inc.	4,150	$47K	0.0%	N/A	0.015%
8/6/2021	Nisa Investment Advisors LLC	4,500	$51K	0.0%	N/A	0.016%
8/5/2021	GSA Capital Partners LLP	93,259	$1.05M	0.1%	N/A	0.340%
7/30/2021	Alliancebernstein L.P.	19,100	$0.22M	0.0%	+7.9%	0.070%
7/30/2021	Kornitzer Capital Management Inc. KS	728,236	$8.23M	0.1%	+1.2%	2.657%
5/19/2021	Virtu Financial LLC	10,200	$0.16M	0.0%	N/A	0.037%
5/18/2021	Millennium Management LLC	33,418	$0.51M	0.0%	-90.0%	0.122%
5/17/2021	Schonfeld Strategic Advisors LLC	44,313	$0.67M	0.0%	N/A	0.162%

Data available starting January 2016

See Full Table

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

Today's Range

Now: $0.43

$0.42

$0.47

50 Day Range

MA: $0.65

$0.43

$0.74

52 Week Range

Now: $0.43

$0.42

$11.41

Volume

392,815 shs

Average Volume

565,098 shs

Market Capitalization

$39.74 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.44

Who are the company insiders with the largest holdings of Verrica Pharmaceuticals?: Verrica Pharmaceuticals' top insider investors include:
Paul B Manning (Director)
Perceptive Advisors Llc (Major Shareholder)
Ted White (CEO)
Christopher G Hayes (Insider)
Joe Bonaccorso (Insider)
Learn More about top insider investors at Verrica Pharmaceuticals.
Who are the major institutional investors of Verrica Pharmaceuticals?: Verrica Pharmaceuticals' top institutional shareholders include:
Caligan Partners LP — 16.29%
Boothbay Fund Management LLC — 5.67%
Geode Capital Management LLC — 1.05%
Sovran Advisors LLC — 0.89%
Heights Capital Management Inc. — 0.77%
Rhumbline Advisers — 0.58%
Learn More about top institutional investors of Verrica Pharmaceuticals stock.
Which major investors are selling Verrica Pharmaceuticals stock?: During the last quarter, VRCA stock was sold by these institutional investors:
XTX Topco Ltd
SteelPeak Wealth LLC
Citadel Advisors LLC
Within the last year, company insiders that have sold Verrica Pharmaceuticals company stock include:
Paul B Manning (Director)
Perceptive Advisors Llc (Major Shareholder)
Ted White (CEO)
Learn More investors selling Verrica Pharmaceuticals stock.
Which major investors are buying Verrica Pharmaceuticals stock?: Within the previous quarter, VRCA stock was bought by institutional investors including:
Caligan Partners LP
Boothbay Fund Management LLC
Sovran Advisors LLC
Heights Capital Management Inc.
Rhumbline Advisers
Bank of America Corp DE
Renaissance Technologies LLC
Invesco Ltd.
During the previous year, these company insiders have bought Verrica Pharmaceuticals stock:
Paul B Manning (Director)
Perceptive Advisors Llc (Major Shareholder)
Learn More investors buying Verrica Pharmaceuticals stock.